Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.

Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, Hogewoning CJ, Zaal A, Verheijen RH, Snijders PJ, Meijer CJ.

Lancet Oncol. 2011 May;12(5):441-50. doi: 10.1016/S1470-2045(11)70078-X.

PMID:
21530398
2.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
3.

HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3.

Zielinski GD, Rozendaal L, Voorhorst FJ, Berkhof J, Snijders PJ, Risse EJ, Runsink AP, de Schipper FA, Meijer CJ.

Gynecol Oncol. 2003 Oct;91(1):67-73.

PMID:
14529664
4.

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.

Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ.

Lancet Oncol. 2012 Jan;13(1):78-88. doi: 10.1016/S1470-2045(11)70296-0. Epub 2011 Dec 14.

PMID:
22177579
5.

Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear.

Berkhof J, Bulkmans NW, Bleeker MC, Bulk S, Snijders PJ, Voorhorst FJ, Meijer CJ.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1268-73.

6.

High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis.

Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, Meijer CJ.

Gynecol Oncol. 2012 May;125(2):500-7. doi: 10.1016/j.ygyno.2012.01.015. Epub 2012 Jan 18. Review.

PMID:
22266548
7.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
8.

Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation.

Heymans J, Benoy IH, Poppe W, Depuydt CE.

Int J Cancer. 2011 Aug 15;129(4):903-9. doi: 10.1002/ijc.25745. Epub 2011 Feb 11.

9.

Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.

Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, Poppe W.

BJOG. 2006 Nov;113(11):1303-7. Epub 2006 Sep 15.

10.

HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.

Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij W, Snijders PJ, Meijer CJ.

Br J Cancer. 2012 Feb 28;106(5):975-81. doi: 10.1038/bjc.2011.581. Epub 2012 Jan 17.

11.

Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing.

Kocken M, Berkhof J, van Kemenade FJ, Louwers JA, Zaal A, Nobbenhuis MA, Kenter G, Snijders PJ, Meijer CJ, Helmerhorst TJ.

Br J Cancer. 2012 Feb 28;106(5):817-25. doi: 10.1038/bjc.2012.5. Epub 2012 Feb 14.

12.

High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.

Persson M, Brismar Wendel S, Ljungblad L, Johansson B, Weiderpass E, Andersson S.

Oncol Rep. 2012 Jul;28(1):346-52. doi: 10.3892/or.2012.1755. Epub 2012 Apr 3.

PMID:
22484610
13.
14.

Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease.

Bais AG, Eijkemans MJ, Rebolj M, Snijders PJ, Verheijen RH, van Ballegooijen M, Meijer CJ, Helmerhorst TJ.

Int J Cancer. 2009 Feb 15;124(4):889-95. doi: 10.1002/ijc.23824.

15.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
16.

Cytology and human papillomavirus screening test results associated with 2827 histopathologic diagnoses of cervical intraepithelial neoplasia 2/3.

Zhao C, Amin M, Weng B, Chen X, Kanbour-Shakir A, Austin RM.

Arch Pathol Lab Med. 2013 Jul;137(7):942-7. doi: 10.5858/arpa.2012-0307-OA. Epub 2012 Oct 10.

PMID:
23050808
17.

Testing for high risk human papilloma virus in the initial follow-up of women treated for high-grade squamous intraepithelial lesions.

Smart OC, Sykes P, Macnab H, Jennings L.

Aust N Z J Obstet Gynaecol. 2010 Apr;50(2):164-7. doi: 10.1111/j.1479-828X.2009.01132.x.

PMID:
20522074
18.

Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.

Derchain SF, Sarian LO, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo RC, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K.

J Med Screen. 2008;15(2):97-104. doi: 10.1258/jms.2008.007061.

PMID:
18573778
19.

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.

Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group.

J Natl Cancer Inst. 2006 Jun 7;98(11):765-74.

PMID:
16757701
20.

Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.

Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ.

Br J Cancer. 2012 Dec 4;107(12):1917-24. doi: 10.1038/bjc.2012.489. Epub 2012 Nov 20.

Supplemental Content

Support Center